Investing.com - Rallybio reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations.
Rallybio announced earnings per share of $-0.60 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.50 on revenue of $0.00.
Rallybio shares are down 32% from the beginning of the year, still down 58.95% from its 52 week high of $21.00 set on November 10, 2021.
Rallybio follows other major Healthcare sector earnings this month
Rallybio's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar